Glioma
Conditions
Interventions
Gold Standard:1. Surgical molecular genotyping (for newly diagnosed glioma cases)
2. MRI follow-ups within half a year or surgery pathology (for suspected recurrence of gliomas after operation)
Index test:18F-FET 
imaging
Sponsors
Huashan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patients with malignant glioma; 2. Patients diagnosed by preoperative enhanced MRI and confirmed by postoperative pathological report; 3. At the review within 12 weeks after the end of postoperative chemoradiotherapy, MRI suspected early recurrence; 4. Age: above 18 years old, below 70 years old; 5. Neutrophils before treatment>2.0x10^9/L, platelet>100 x 10^9/L; Total bilirubin 50 ml/min; 6. the informed consent signed.
Exclusion criteria
Exclusion criteria: 1. Previous history of other malignant tumors; 2. Other physical diseases that affect the patients to receive standard treatment; 3. Positive pregnancy test for women of childbearing age; 4. Active mental disorders or other mental disorders that affect patients' ability to sign informed consent and understand; 5. Serious treatment-related adverse events or serious adverse reactions; 6. The patient asked to withdraw from the study; 7. Serious violations of the research programme; 8. After discussion, the investigator concluded that the patient should terminate the clinical trial; 9. Failed to complete 18F-FET PET/CT imaging and subsequent MRI follow-up as required; 10. Failure to obtain a surgical pathology organizer; 11. Lost to follow-up cases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| mutant isocitrate dehydrogenase, IDH-mut;O6-methylguanine methyltransferase (MGMT) promoter methylation;1p/19q codeletion;Early recurrence or pseduprogression; | — |
Countries
China
Contacts
Public ContactWeiyan Zhou
Outcome results
None listed